Milife®
Milife
1574 Items
2019-09-19
- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Clinical Pharmacology
Pharmacological group: adaptogenic agent.
Pharmacological action: Pharmacological action - metabolic, tonic, adaptogenic, regenerating, detoxifying, immunomodulating, antiviral, genoprotective, antimalarial, antiparasitic.
The range of effects of the resulting effects when using the drug is so wide that it allows to classify it as a systemic drug that detects and restores informational violations (restoration of correct genetic replications), functional, metabolic, energy bonds in the body, activating regenerative, reparative processes at different levels. Such possibilities of the drug are due to a powerful antioxidant effect (blockade of the final stages of oxidative stress). It has a non-specific and specific antiviral effect.
A variety of biologically active compounds, approaching in chemical composition to the complex membrane structure of a human cell, determines the multivalence of the influence of Milife® on metabolic-endocrine-immune processes, exerting a corrective effect on all types of metabolism and homeostasis as a whole.
It is a biomass of monoculture of the higher mushroom Fusarium sambucinum, strain BAB-917. Contains low molecular weight oligopeptide compounds, alkaline oligopeptides, 18 amino acids, including all essential amino acids, which account for up to 45% of the total number of amino acids of the drug.
The carbohydrate composition of the drug includes biologically active polysaccharides (glycans: glucans and galactomannans, lentinan).
In addition, oxalic, malic, citric, succinic and other organic acids are part of Milyife®.
The lipid fraction of the drug contains phospholipids, sterols, glycerides, fatty acids and ubiquinones.
More than 50% of the fatty acids that make up the Milife® preparation come from essential linoleic and linolenic acids, which are not synthesized in the human body and must come from food.
Milife® contains the full range of B vitamins.
Milife® contains a balanced set of macro- and microelements in an easily digestible form of organic compounds and complexes.
From the first days of administration, the positive activity of Milife® begins to manifest itself at the molecular-cellular level in those organs and systems that have the most profound and gross violations.
Milife®, acting on the mesodiencephalic structures of the brain, finds “Locus minoris” (“the place of least resistance”) in the body and acts on it selectively and consistently.
Milife® has a tonic and adaptogenic effect, increases the body's resistance to the effects of an endo-ecological environment, increases the body's resistance to stress, preventing secondary post-stress effects. Increases mental and physical performance, as well as accelerates the recovery after suffering loads and diseases of various etiologies. This is made possible by the powerful antioxidant effect of the drug.
Milife® increases the proliferative activity (division activity) in cells and controls the cell cycle, triggers an accelerated system of apoptosis in defective cells, which slows down the accumulation of mutations.
Milife® releases cells from genetically abundant (extrachromosomal) DNA as a result of increased vesicular traffic (intracellular and intercellular transport in membrane vesicles). The result of this is the suppression of defective and increase the accuracy of replication of existing sequences in DNA, which allows the use of the Milife® preparation for the prevention of cancer and for the suppression of the progression of malignant cells during cancer therapy.
Milife® has a bioregulatory multidirectional effect that can strengthen the weak, weaken the strong or leave the normal response of the immune system unchanged.
As a result of experimental studies and clinical trials, it has been established that Milife® affects immunocompetent organs, contributes to the normalization of indicators of both cellular and humoral immunity. It causes the effect of colony-stimulating factor in immunocompetent organs, increasing the lymphoid cells by 1.7–2.1 times. Restores the entire interleukin series (from IL-1 to IL-18). As an inducer of alpha, beta and gamma interferon, tumor necrosis factor (alpha / beta), the drug increases the number of natural killer cells (CD16), increases the number of B-lymphocytes, increases the immunoregulatory index (the ratio of helper and suppressor) due to an increase in cytotoxic T lymphocytes (CD8) and T-helper cells (CD4).
Considering the effect of Milife® on immunocompetent organs and the enhancement of vesicular traffic, the neuroimmune system is able to recognize pathological changes in the cell and the cause of these changes, in particular, the virus. The consequence of this is the specific and non-specific antiviral effect of the drug. Milife® allows induction of cellular and humoral immunity by increasing cytotoxic T-lymphocytes (CTLs), which recognize presented antigens by restoring the function of proteins of the main histocompatibility complex (MHC) and lyse infected cells. Milife® has a direct virucidal action, i.e. destroys the virus by acting directly on its structure, even if the virus is in a latent form. Promotes the elimination of the virus, by eliminating the cells that produce the virus. Against the background of the action of the drug, B-lymphocytes form a wide spectrum of soluble antibodies that neutralize the virus, and support the immune response by increasing the number of active B-lymphocytes of prolonged memory and increasing the duration of persistent expression of the virus antigen. The drug even contributes to the inactivation of the virus until the moment when he has a chance to infect new host cells. Formed antibodies mobilize the inflammatory system, including the complement system, neutrophils and monocytes. Thus, even when the antibodies do not neutralize the virus directly, there is a possibility that other effector functions of the antibodies will be enhanced through the use of an inflammatory system. The drug does not allow the virus to acquire the properties of resistance and evolve.
A wide range of antiviral activity of the drug indicates the presence of pronounced immunological mechanisms of action, which is confirmed by studies conducted in the Institute of Epidemiology and Microbiology. N.F. Gamaley and the Research Institute of Virology and Epidemiology. Ivankovskogo.
Milife® has a specific activity against Plasmodium vivax, Plasmodium falciparum and Plasmodium malariae both in the prophylactic regimen and in the administration of the drug 72 and 96 hours after infection.
The data on the high specific activity of the drug Milayf® against Plasmodium vivax, Plasmodium falciparum and Plasmodium malariae are consistent with those of pronounced antiviral and immunostimulatory activity Milayf®pri preparation of experimental influenza infection, infections caused by viruses of encephalitis and other viruses, and confirm its antiparasitic action ( yellow fever, malaria, toxoplasmosis and leishmaniasis).
Milife® has a hepatoprotective effect, normalizes impaired detoxification and protein-forming function of the liver due to the activation of many isoforms of cytochrome P450.
Milife® does not contain doping components (Expert opinion No. S068S of the anti-doping center of May 24, 2008) and can be recommended for widespread use in sports medicine.
On the basis of the work performed, it can be stated that Milife® during course application restores the physical and mental performance of athletes, has a simulating effect on clinical, biochemical and immunological blood parameters.
Pharmacokinetics: After oral administration, the drug is rapidly absorbed. Maximum activity is reached after 90 minutes. Bioavailability is almost complete. The degree of binding to plasma proteins is up to 6%, the volume of distribution is 1.8–1.9 l / kg.
The drug quickly penetrates the tissues, organs and biological body fluids - cardiac muscle and heart valves, liver, spleen, adrenal glands, kidneys, gall bladder, pancreas, uterus, prostate gland, bones, abdominal and pleural cavities, saliva, sputum. The concentration of Milife® in tissues and organs is higher than the concentration in the blood plasma.
The drug is excreted mainly in the urine (up to 70% within 72 hours) and partly with bile - up to 25%.
Indications
chronic fatigue syndrome and immune dysfunction;
complex therapy for the treatment of viral and toxic liver damage (including alcoholic origin);
immunodeficiency and immunodepression;
complex therapy in the treatment of autoimmune diseases (autoimmune thyroiditis, diabetes mellitus);
as a therapeutic and prophylactic agent for influenza, latent forms of herpes (6 types of herpes), chlamydial, ureaplasmosis infections; infections of HIV and hepatitis C, as well as infections caused by pathogens of yellow fever and malaria;
radiotherapy and chemotherapy in cancer patients;
the period of preoperative preparation and postoperative rehabilitation;
neuroendocrine disorders (mastopathy, ovarian dysfunction and their cystic changes, uterine myoma, endometriosis, infertility);
various manifestations of climacteric syndrome;
persons engaged in physical culture and sports (any age category - from junior to veteran age) in training and competition cycles, as a means of increasing efficiency and increasing the threshold of fatigue;
rehabilitation of athletes after injuries and when leaving the "big" sport.
No customer reviews for the moment.
Dosage and Administration
Substance: to prepare a solution for the treatment of wound surfaces and trophic ulcers, 1 g of the preparation is diluted in 50 ml of distilled water.
pills: sublingually (dissolve), after meals.
Capsules: inside, after meals.
In the process of studying the effect of the drug, two dosages were worked out that affect the body systems and the body as a whole - 50 mg and 1 g.
The use of different dosages and their alternation is determined by specific prophylactic and therapeutic tasks. At a dose of 100 mg 3 times a day, the broken bonds in the body are found and restored at the molecular and submolecular level, subjectively, this is manifested by various clinical symptoms of chronic pathology that a person has. At a dose of 1 g from 6 to 12 times a day, a positive effect on the pathological focus is directly carried out and the replacement of defective cells takes place, subjectively, the relief of clinical manifestations occurs.
Selection of the regimen for taking Milife® is individual and depends on the initial status (immunological, neurohumoral, etc.).
The starting scheme for taking the drug Milif®:
1. From 1 to 5 day: 100 mg 3 times a day.
2. From day 6 for 12 weeks: Monday, Tuesday, Wednesday - 100 mg 3 times a day; Thursday, Friday, Saturday, Sunday - 1 g 3 times a day.
3. For women: intravaginally 200 mg, for 30 days (with the exception of menstruation days) from the 6th day of taking Milife®.
4. Cedar oil, 1 des.lokk 1 times per days of taking Milife® 1 g each (Thursday, Friday, Saturday, Sunday).
5. Physical exercise (classes).
After receiving the starting regimen, the doctor decides on the need for further intake of Milife® according to an individual regimen.
For athletes and those who are intensively engaged in physical culture, the starting scheme is the same, but in the prelaunch and starting periods the dose increases to 12 g / day (2 g 6 times). This scheme is approved by the Clinical Pharmacology and Anti-Doping Control Laboratory of the Moscow Scientific Practical Center for Sports Medicine.
Adverse reactions
Milife® in any dosage is neither carcinogenic, mutagenic, nor teratogenic, nor embryotoxic.
Milife® does not contain xenobiotics, preservatives and any substances that lead to the development of allergic reactions.
In the process of detailed experimental studies of the drug, no side effects from its use were identified.
Contraindications
individual intolerance to the components of the drug;
diseases of the liver and kidneys (terminal stages of cirrhosis and chronic renal failure.
Drug interactions
Milayf® can be combined with the antibiotic tetracycline, penicillin, cephalosporins, macrolides, nitrofuran derivatives, naphthyridine, drugs ursodeoxycholic and chenodeoxycholic acids, fluoroquinolone drugs, thus reducing the dose of antibiotics to 2/3 patients receiving Milayfa® at 1.0 g 6 times a day for 2–3 days.
Revealed the synergistic interaction of Milife® with gamma-amino-beta-phenylbutyric acid.
Milife® enhances the action of peripheral vasodilators, antiarrhythmic, membrane stabilizing, anticonvulsant, anti-Parkinsonian drugs, NSAIDs, but does not combine with arylcarboxylic acid derivatives and oxycats.
Pregnancy and Lactation
During pregnancy and during breastfeeding, based on the results of long clinical observations, a dose of 100 mg 3 times a day is recommended, and in case of intercurrent diseases (ARVI, flu, etc.), 1 g 6 times for 3-4 days
Special instructions
Based on 15 years of experience observing individuals of different sex and age who took Milife®, the following results were obtained.
The normalization of the level of all indicators (clinical and biochemical) blood.
Marked normalization of T-and B-cell levels of the immune system.
The study of the hormonal profile showed the correlating effect of Milife® on the level of pituitary hormones and ovarian hormones in phase I and II of the menstrual cycle, and a significant increase in progesterone in the ovulation phase of the menstrual cycle.Anovulatory cycle is not observed in any of the women of reproductive age.
The obtained data indicate a reliable stabilization and normalization of the neurohormonal profile in the reproductive ring of the hypothalamus-pituitary-adrenal glands-ovaries, which allows to recommend the drug Milife® to girls of pre- and adolescence in order to relieve the syndrome of psycho-emotional lability, formation and normalization of the menstrual cycle.
Ultrasound revealed a decrease in the size of subserous-interstitially located fibromatous nodes until their complete lysis, in a small percentage of women there was a “birth” of submucously located fibromatous nodes, the cellular structure of myometrium and cystic ovarian degeneration disappeared.
After taking the drug, positive EEG dynamics was revealed in the form of normalization of the alpha rhythm, the appearance of zonal differences, the disappearance of paroxysmal changes during functional loads. The revealed positive EEG dynamics indicates the normalization of the functional state of the mesodiencephalic formations of the brain on the background of taking Milife® in more than 90% of those taking the drug.
In functional studies of cerebral vessels, there were no signs of venous stasis, the blood filling of the carotid arteries improved, the vascular tone in the vertebrobasilar basin was normalized. Milife® improves microcirculation not only by restoring the rheological properties of blood, but also by improving the blood supply to the vessel wall itself (in particular, the epithelium).
Milife® restores previously impaired processes of neurohumoral regulation and myocardial energy resources, which results in improved contractile ability, relaxation function and positive inotropic heart stimulation. Restoration of bioenergetic processes improves the compensatory abilities of the body, contributing to the work of the heart in a more economical mode.
In chronic latent forms of genital herpes and chlamydia, a massive release of infectious agents from cells and their subsequent elimination was found, which is associated with the development of a “short” immunity by the body. This contributed to the restoration of the microscopic structure of the mucous and muscle fibers of smooth muscles.
The drug Milife® with course application for 21 days increases the overall athletic performance of athletes by at least 30%, which results in an increase in the running time to failure on the treadmill with stepwise increased physical activity.
Revealed a powerful antioxidant effect of the drug at the same time. Morphologically, this effect was expressed in the stabilization of muscle mass against the background of fat mobilization, whereas in the control group there were signs of maladaptation to similar loads in the form of a total reduction of three morphological indicators (body weight, muscle mass, fat mass).
The drug Milife® with course application prevents an increase in the concentration of urea in the blood of athletes (statistically significantly 17.8%), as well as a decrease in the hematocrit and lactate levels. An increase in the contractile ability of the myocardium and an improvement in the propulsive work of the heart were noted.
The economization of the circulatory system function was achieved by increasing the ability of the muscles to use oxygen and improving the ability to isotonic contraction of the heart muscle.
Positive dynamics was observed on the part of the contractility of the myocardium and the phase structure of systole. The extension of the pre-expulsion period indicated an improvement in the ability of the myocardium to create the necessary tension for a powerful contraction.The reduced value of intraventricular pressure created conditions for reducing the voltage in the wall of the left ventricle, which, together with reduced systolic indexes of the thickness of the posterior wall of the left ventricle and its size, contributed to a certain decrease in systolic meridional and circulatory stresses and an increase in the structure functioning index values. Evaluation of diastolic function showed an improvement in the ability of myocardiocytes to accumulate the necessary energy reserve.
Restores immunological reactivity in high-class athletes, which is reflected in the normalization of a reduced concentration of immunoglobulins A, M and G; normalizes reduced due to debilitating physical exertion in athletes who train for the development of endurance, the level of the components of the NW and C4.
Favorably affects the links of cellular immunity (phagocytic activity, phagocytosis intensity, lysosome activity, monocyte activity, increases the number of T and B lymphocytes). Normalizes nonspecific protection factors, such as alpha-1-glycoprotein and alpha-2-glycoprotein levels, while seromucoid and haptoglobin concentrations remain almost unchanged.
- Brand name: Milife
Customers who bought this product also bought:
8 other products in the same category:
arrow_upward